Morepen Laboratories To Hive Off Medical Devices Business

New Delhi:  Pharmaceutical company Morepen Laboratories Ltd on Tuesday (January 14) said its board has approved the hiving off of its medical devices business to its newly incorporated subsidiary, Morepen Medtech Ltd, on a slump sale basis as a going concern. The transaction is subject to requisite regulatory and shareholder approvals.

“This is to inform that the Board of Directors (the ‘Board’) of the company at their meeting held today i.e., Tuesday, January 14, 2025 (commenced at 5.00 p.m. and concluded at 6.40 p.m.), has, inter-alia, considered and approved the hiving of the Medical Devices Business, being an undertaking, to Morepen Medtech Limited, a subsidiary of the company, on a ‘slump sale’ basis as a going concern,” Morepen Laboratories said in a regulatory filing.

The decision, taken during the board meeting held on January 14, aims to provide operational independence and a concentrated focus on the medical devices segment. Morepen Medtech Limited, incorporated on January 8, 2025, will take over the business upon fulfilment of all conditions precedent.

The Business Transfer Agreement (BTA) is yet to be executed, and the transaction is expected to be completed by September 30, 2025. The consideration for the sale will be determined based on an independent valuation of assets and liabilities in compliance with Rule 11UAE of the Income Tax Rules, 1962.

Morepen Medtech, a subsidiary of Morepen Laboratories, will have an aggregate promoter group shareholding of 20%. The transaction qualifies as a related-party transaction but will be conducted on an arm’s length basis, with requisite member approvals obtained.

Related Posts

  • Pharma
  • February 17, 2025
  • 72 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 66 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%